{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:07:08Z","timestamp":1783426028146,"version":"3.54.6"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st","doi-asserted-by":"crossref","award":["2018012"],"award-info":[{"award-number":["2018012"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st","doi-asserted-by":"crossref","award":["2019096"],"award-info":[{"award-number":["2019096"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Motivation<\/jats:title>\n                  <jats:p>There is a rapidly growing interest in high-throughput drug combination screening to identify synergizing drug interactions for treatment of various maladies, such as cancer and infectious disease. This creates the need for pipelines that can be used to design such screens, perform quality control on the data and generate data files that can be analyzed by synergy-finding bioinformatics applications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>screenwerk is an open-source, end-to-end modular tool available as an R-package for the design and analysis of drug combination screens. The tool allows for a customized build of pipelines through its modularity and provides a flexible approach to quality control and data analysis. screenwerk is adaptable to various experimental requirements with an emphasis on precision medicine. It can be coupled to other R packages, such as bayesynergy, to identify synergistic and antagonistic drug interactions in cell lines or patient samples. screenwerk is scalable and provides a complete solution for setting up drug sensitivity screens, read raw measurements and consolidate different datasets, perform various types of quality control and analyze, report and visualize the results of drug sensitivity screens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Availability and implementation<\/jats:title>\n                  <jats:p>The R-package and technical documentation is available at https:\/\/github.com\/Enserink-lab\/screenwerk; the R source code is publicly available at https:\/\/github.com\/Enserink-lab\/screenwerk under GNU General Public License v3.0; bayesynergy is accessible at https:\/\/github.com\/ocbe-uio\/bayesynergy. Selected modules are available through Galaxy, an open-source platform for FAIR data analysis at https:\/\/oncotools.elixir.no<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Supplementary information<\/jats:title>\n                  <jats:p>Supplementary data are available at Bioinformatics online.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bioinformatics\/btac840","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T14:33:54Z","timestamp":1672065234000},"source":"Crossref","is-referenced-by-count":3,"title":["screenwerk: a modular tool for the design and analysis of drug combination screens"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-2182","authenticated-orcid":false,"given":"Robert","family":"Hanes","sequence":"first","affiliation":[{"name":"Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital , 0379 Oslo, Norway"},{"name":"Centre for Cancer Cell Reprogramming, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo , 0318 Oslo, Norway"},{"name":"Section for Biochemistry and Molecular Biology, Faculty of Mathematics and Natural Sciences, University of Oslo , 0316 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ayuda-Dur\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital , 0379 Oslo, Norway"},{"name":"Centre for Cancer Cell Reprogramming, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo , 0318 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiv","family":"R\u00f8nneberg","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo , 0317 Oslo, Norway"},{"name":"MRC Biostatistics Unit, University of Cambridge , Cambridge CB2 0SR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-2050","authenticated-orcid":false,"given":"Sigve","family":"Nakken","sequence":"additional","affiliation":[{"name":"Centre for Cancer Cell Reprogramming, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo , 0318 Oslo, Norway"},{"name":"Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital , Oslo 0379, Norway"},{"name":"Department of Informatics, Centre for Bioinformatics, University of Oslo , Oslo 0372, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9103-1077","authenticated-orcid":false,"given":"Eivind","family":"Hovig","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital , Oslo 0379, Norway"},{"name":"Department of Informatics, Centre for Bioinformatics, University of Oslo , Oslo 0372, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-7422","authenticated-orcid":false,"given":"Manuela","family":"Zucknick","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo , 0317 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-5387","authenticated-orcid":false,"given":"Jorrit M","family":"Enserink","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital , 0379 Oslo, Norway"},{"name":"Centre for Cancer Cell Reprogramming, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo , 0318 Oslo, Norway"},{"name":"Section for Biochemistry and Molecular Biology, Faculty of Mathematics and Natural Sciences, University of Oslo , 0316 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"2023010806153865100_btac840-B1","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"2023010806153865100_btac840-B2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","article-title":"Principles and mechanisms of non-genetic resistance in cancer","volume":"122","author":"Bell","year":"2020","journal-title":"Br. J. Cancer"},{"key":"2023010806153865100_btac840-B3","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1158\/0008-5472.CAN-21-3605","article-title":"How compensatory mechanisms and adaptive rewiring have shaped our understanding of therapeutic resistance in cancer","volume":"81","author":"Bergholz","year":"2021","journal-title":"Cancer Res"},{"key":"2023010806153865100_btac840-B4","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl. J. Med"},{"key":"2023010806153865100_btac840-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/2211738507666190122111224","article-title":"Drug combinations in breast cancer therapy","volume":"7","author":"Fisusi","year":"2019","journal-title":"Pharm. Nanotechnol"},{"key":"2023010806153865100_btac840-B6","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl. J. Med"},{"key":"2023010806153865100_btac840-B7","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1158\/0008-5472.CAN-14-0725","article-title":"Enhancing reproducibility in cancer drug screening","volume":"74","author":"Hatzis","year":"2014","journal-title":"Cancer Res"},{"key":"2023010806153865100_btac840-B8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma. A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2023010806153865100_btac840-B9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"2023010806153865100_btac840-B10","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder. A web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"2023010806153865100_btac840-B11","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1038\/s41598-020-62848-5","article-title":"Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens","volume":"10","author":"Larsson","year":"2020","journal-title":"Sci. Rep"},{"key":"2023010806153865100_btac840-B12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41467-020-20378-8","article-title":"BRD4-mediated repression of p53 is a target for combination therapy in AML","volume":"12","author":"Latif","year":"2021","journal-title":"Nat. Commun"},{"key":"2023010806153865100_btac840-B13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1101\/gad.186965.112","article-title":"Complexity in the signaling network. Insights from the use of targeted inhibitors in cancer therapy","volume":"26","author":"Logue","year":"2012","journal-title":"Genes Dev"},{"key":"2023010806153865100_btac840-B14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1634\/theoncologist.2012-0391","article-title":"Ipilimumab, vemurafenib, dabrafenib, and trametinib. Synergistic competitors in the clinical management of BRAF mutant malignant melanoma","volume":"18","author":"Luke","year":"2013","journal-title":"Oncologist"},{"key":"2023010806153865100_btac840-B15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies. Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"2023010806153865100_btac840-B16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cels.2019.06.005","article-title":"A multi-center study on the reproducibility of drug-response assays in mammalian cell lines","volume":"9","author":"Niepel","year":"2019","journal-title":"Cell Syst"},{"key":"2023010806153865100_btac840-B17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy. Implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov"},{"key":"2023010806153865100_btac840-B18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl. J. Med"},{"key":"2023010806153865100_btac840-B19","doi-asserted-by":"crossref","first-page":"bbab251","DOI":"10.1093\/bib\/bbab251","article-title":"Bayesynergy. Flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments","volume":"22","author":"R\u00f8nneberg","year":"2021","journal-title":"Brief. Bioinform"},{"key":"2023010806153865100_btac840-B20","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1158\/0008-5472.CAN-17-1201","article-title":"Combination therapy and the evolution of resistance. The theoretical merits of synergism and antagonism in cancer","volume":"78","author":"Saputra","year":"2018","journal-title":"Cancer Res"},{"key":"2023010806153865100_btac840-B21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMcibr1013704","article-title":"Resistance to BRAF inhibition in melanomas","volume":"364","author":"Solit","year":"2011","journal-title":"N Engl. J. Med"},{"key":"2023010806153865100_btac840-B22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2307\/2530598","article-title":"Application of the four-parameter logistic model to bioassay. Comparison with slope ratio and parallel line models","volume":"34","author":"V\u00f8lund","year":"1978","journal-title":"Biometrics"},{"key":"2023010806153865100_btac840-B23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Target. Ther"},{"key":"2023010806153865100_btac840-B24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformatics\/advance-article-pdf\/doi\/10.1093\/bioinformatics\/btac840\/48420126\/btac840.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/39\/1\/btac840\/48521765\/btac840.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/39\/1\/btac840\/48521765\/btac840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T06:16:54Z","timestamp":1673158614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/doi\/10.1093\/bioinformatics\/btac840\/6961189"}},"subtitle":[],"editor":[{"given":"Jonathan","family":"Wren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/btac840","relation":{},"ISSN":["1367-4811"],"issn-type":[{"value":"1367-4811","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,12,27]]},"article-number":"btac840"}}